Clinical Trial

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2022 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-07-02.
Status change: Not Yet Recruiting → Recruiting 2022-06-03
Trial Details
NCT Number NCT04458688
Lead Sponsor Wayne State University
Conditions Multiple Sclerosis, Relapsing-Remitting
Enrollment 80 participants
Start Date 2021-11-20
Primary Completion 2025-07 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2022-06-06